Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Peter Silsbee who wrote (244)	1/29/1998 6:26:00 PM
From: lrb	Read Replies (2) \| Respond to of 1494

"the potential to be at least as effective as the current standard treatment for the condition" does not sound so bad to me in light of "current standard treatment for peritumoral brain edema, is associated with serious adverse effects including muscle wasting, gastrointestinal bleeding, osteoporosis, and central nervous system effects ranging from personality changes to frank psychoses." together with "In over 230 courses of treatment in NTI-sponsored studies, Xerecept was well-tolerated and appeared to be safe"